… that selectively targeting BCR-ABL with nilotinib is an important therapeutic option for patients
who have progressed to advanced phase Ph+ CML. Nilotinib treatment resulted in a high …

… with imatinib (40%). Superior rates of MMR were observed in both nilotinib arms compared
with the imatinib … The overall best rate of BCR-ABL IS ≤ 0.0032% (equivalent to complete …

… combined with nilotinib in imatinib-resistant Ba/F3 cells carrying point mutations in the ABL
TK … revealed a significant enhancement of nilotinib-induced apoptosis in imatinib-resistant Ba/…

… nilotinib seem to target stem-cell subsets. Effective models must take this into account. …
imatinib follow-up drugs dasatinib and nilotinib inhibit the majority of imatinib-resistant BCR–ABL …

… between the TKI C m i n ∞ (imatinib and nilotinib) and BCR-ABL ratio in patients with
chronic phase CML who had used TKI, either imatinib or nilotinib, for ≥12 months therapy. …

… Imatinib and nilotinib were utilized as the positive controls to validate the screening assay. …
, Imatinib and nilotinib displayed IC 50 values of 309 and 39.3 nM against Bcr/Abl fused kinase…

… We thus performed cytotoxicity assays with imatinib, nilotinib, or dasatinib on BCR-ABL-positive
parental K562 cells as well as transduced K562-ABCG2 and K562-ABCB1 cells, with …

… Similar to imatinib, nilotinib binds to the inactive conformation of ABL kinase, thereby …
indicate that nilotinib has a higher affinity for the ABL kinase domain than imatinib, resulting …

… nilotinib and imatinib. Microarray-based transcriptome profiling of resistant cells revealed that
nilotinib- and imatinib-… and FYN was observed both in nilotinib- and imatinib-resistant cells …

… more potent than imatinib against Bcr-Abl kinase. However, nilotinib is less potent than
dasatinib and has a more restricted spectrum of kinase inhibition. Moreover, nilotinib's in vivo half-…